Dr. Reddy's Laboratories (RDY) on Wednesday announced that India’s drug regulator, the Drugs Controller General of India, has issued marketing and manufacturing authorization for a generic version of ...

Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain territories while leaving the Australian biotech with ownership in key ...

What are music’s biggest global artist stories of 2025? Here’s a trio for you: Taylor Swift’s record-shattering The Life Of A Showgirl; Bad Bunny’s culture-defining residency in Puerto Rico (and ...

A Syracuse television station is being disrupted by a planned change in its call letters and channel position. CNY Central’s WTVH CBS 5 changed its call letters on Monday, Dec. 1, becoming WKOF CBS 5.

Update: CNY Central said Monday afternoon it is aware of issues for Verizon FiOS and Spectrum customers who are unable to access its CBS programming on WKOF, or can’t find it in the channel guide.

The Nevada women's basketball team hosts San Diego State on Saturday afternoon at Lawlor Events Center. The game will air on Nevada Sports Net, and you can watc Washoe County H.E.R.O. team arrests man ...

Comcast's new arm, Versant, is rebranding its sports division to USA Sports. The Golf Channel will keep its name but will feature new branding, removing NBC logos. USA Sports will continue to ...

The leadership change was made by Digital Domain's board of directors and key investors and follows the exit of former president and COO Lala Gavgavian. By Winston Cho Sudhir Reddy has been named the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min AAR's $78M acquisition of HAECO ...

Oct 30 (Reuters) - Shares of Indian generic drugmaker Dr Reddy's Laboratories (REDY.NS), opens new tab declined more than 5% on Thursday, after the firm received a non-compliance notice for its ...

Dr. Reddy’s Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, ...